INT190676

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.36
First Reported 2006
Last Reported 2010
Negated 2
Speculated 0
Reported most in Body
Documents 15
Total Number 15
Disease Relevance 3.11
Pain Relevance 0.28

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

isomerase activity (Fkbp1a) protein folding (Fkbp1a) cytosol (Fkbp1a)
signal transduction (Fkbp1a) enzyme binding (Fkbp1a) cytoplasm (Fkbp1a)
Anatomy Link Frequency
T cell 4
Fkbp1a (Mus musculus)
Pain Link Frequency Relevance Heat
cytokine 127 98.44 Very High Very High Very High
Inflammation 62 87.60 High High
corticosteroid 186 31.40 Quite Low
fibrosis 52 5.00 Very Low Very Low Very Low
Bioavailability 30 5.00 Very Low Very Low Very Low
Paracetamol 15 5.00 Very Low Very Low Very Low
antagonist 11 5.00 Very Low Very Low Very Low
agonist 11 5.00 Very Low Very Low Very Low
Antihistamine 10 5.00 Very Low Very Low Very Low
tolerance 10 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Apoptosis 44 99.56 Very High Very High Very High
Tuberous Sclerosis 67 97.68 Very High Very High Very High
Carcinoma 10 93.12 High High
Sprains And Strains 19 92.24 High High
Bacterial Respiratory Disease 2 89.80 High High
Adhesions 16 88.76 High High
INFLAMMATION 62 87.60 High High
Infection 21 77.04 Quite High
Organ Transplantation 27 75.40 Quite High
Neurodegenerative Disease 11 75.32 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Despite the structural homology between sirolimus and tacrolimus with both drugs binding to the same intracellular immunophilin, FK506 binding protein, a 12-kDa binding protein (FK Binding protein-12) in T cells, the two drugs act synergistically rather than competitively and also differ in their mechanism of action.
a 12-kDa Binding (binding) of in T cells
1) Confidence 0.36 Published 2009 Journal Journal of Transplantation Section Body Doc Link PMC2809333 Disease Relevance 0.20 Pain Relevance 0
Despite the structural homology between sirolimus and tacrolimus with both drugs binding to the same intracellular immunophilin, FK506 binding protein, a 12-kDa binding protein (FK Binding protein-12) in T cells, the two drugs act synergistically rather than competitively and also differ in their mechanism of action.
a 12-kDa Binding (binding) of in T cells
2) Confidence 0.36 Published 2009 Journal Journal of Transplantation Section Body Doc Link PMC2809333 Disease Relevance 0.19 Pain Relevance 0
The immunosuppressives cyclosporine A (CsA) and FK506 which bind to Cyclophilin A (CyA) and FKBP12, respectively, prevent NF-AT mediated cytokine gene transcription [6].
FKBP12 Binding (bind) of associated with cytokine
3) Confidence 0.20 Published 2007 Journal PLoS ONE Section Body Doc Link PMC1790862 Disease Relevance 0.51 Pain Relevance 0.28
In mammalian cells, rapamycin forms a complex with the immunophilin FKBP12 (FK506-binding protein of 12 kDa), which binds to mTORC1 and inhibits its activity (Fig. 2) (27).
immunophilin FKBP12 Binding (complex) of
4) Confidence 0.12 Published 2010 Journal The Journal of Biological Chemistry Section Body Doc Link PMC2856980 Disease Relevance 0.19 Pain Relevance 0
It has been shown that the sirolimus/FKBP12 complex, but not FK506/FKBP12 complex, binds with very high affinity to mTOR.
FKBP12 Binding (binds) of
5) Confidence 0.11 Published 2008 Journal Current Genomics Section Body Doc Link PMC2691673 Disease Relevance 0.22 Pain Relevance 0
Studies on sirolimus activity have shown that it binds to its intracellular receptor FKBP12 (FK506-binding protein 12), a member of the family of FK506-binding proteins.
FKBP12 Binding (binds) of
6) Confidence 0.11 Published 2008 Journal Current Genomics Section Body Doc Link PMC2691673 Disease Relevance 0.19 Pain Relevance 0
It has also been demonstrated that the binding of sirolimus to FKBP12 is required for the inhibitory effect of sirolimus on mTOR function [118].
FKBP12 Binding (binding) of
7) Confidence 0.11 Published 2008 Journal Current Genomics Section Body Doc Link PMC2691673 Disease Relevance 0.18 Pain Relevance 0
It has been shown that the sirolimus/FKBP12 complex, but not FK506/FKBP12 complex, binds with very high affinity to mTOR.
FKBP12 Neg (not) Binding (complex) of
8) Confidence 0.11 Published 2008 Journal Current Genomics Section Body Doc Link PMC2691673 Disease Relevance 0.22 Pain Relevance 0
It has been shown that the sirolimus/FKBP12 complex, but not FK506/FKBP12 complex, binds with very high affinity to mTOR.
FKBP12 Neg (not) Binding (complex) of
9) Confidence 0.11 Published 2008 Journal Current Genomics Section Body Doc Link PMC2691673 Disease Relevance 0.22 Pain Relevance 0
It has been shown that the sirolimus/FKBP12 complex, but not FK506/FKBP12 complex, binds with very high affinity to mTOR.
FKBP12 Binding (binds) of
10) Confidence 0.11 Published 2008 Journal Current Genomics Section Body Doc Link PMC2691673 Disease Relevance 0.22 Pain Relevance 0
However, while tacrolimus binds tightly to the cellular protein named FKBP (FK506-binding protein) 12, cyclosporine binds cyclophilin.
FKBP Binding (binds) of
11) Confidence 0.04 Published 2006 Journal BMC Cancer Section Body Doc Link PMC1386691 Disease Relevance 0.09 Pain Relevance 0
It should be further noted, that an even more direct link between tacrolimus and Bcl-2 family proteins results of the finding that the tacrolimus-binding protein FKBP 38 blocks apoptosis, binds to Bcl-2 and targets Bcl-2 to the mitochondria [17].


FKBP Binding (binding) of associated with apoptosis
12) Confidence 0.04 Published 2006 Journal BMC Cancer Section Body Doc Link PMC1386691 Disease Relevance 0.46 Pain Relevance 0
Sirolimus which also binds to the FKBP family, particularly FKBP-12, does not bind to calcineurin but instead binds to target molecules with kinase activity called MTOR (mammalian targets of rapamycin), also known as FRAP and RAFT.
FKBP Binding (binds) of
13) Confidence 0.03 Published 2009 Journal Journal of Transplantation Section Body Doc Link PMC2809333 Disease Relevance 0.05 Pain Relevance 0
The immunosuppressive activity of sirolimus activity is primarily related to blockade of IL-2 and IL-15 induction of B and T cell proliferation via inhibition of p70S6 kinase through high affinity binding to FKBP and prevents progression of the cell cycle from the G1 to S phase.
FKBP Binding (binding) of in T cell
14) Confidence 0.03 Published 2009 Journal Journal of Transplantation Section Body Doc Link PMC2809333 Disease Relevance 0.06 Pain Relevance 0
Csa and tacrolimus (which inhibit the phosphatase calcineurin after binding to heir respective immunophilins FKBP and cyclophilin, respectively) inhibit early events in T cell activation particularly the expression of IL-2 in the G0-G1 stage of the cell cycle.
FKBP Binding (binding) of in T cell
15) Confidence 0.02 Published 2009 Journal Journal of Transplantation Section Body Doc Link PMC2809333 Disease Relevance 0.12 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox